SUShunya Uchida

Shunya Uchida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shunya Uchida has a total of 235 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nicorandil protects podocytes via modulation of antioxidative capacity in acute puromycin aminonucleoside-induced nephrosis in rats

    by Masaki Yamanaka, Yoshifuru Tamura, Emiko Kuribayashi-Okuma, Shunya Uchida, Shigeru Shibata

    Our findings suggest that the mitochondrial Ca2+ uniporter may be an upstream regulator of manganese superoxide dismutase and indicate a biochemical basis for the interaction between the ATP-sensitive K+ channel and Ca2+ signaling. We believe that our study makes a significant contribution to the literature because our results indicate that the ATP-sensitive K+ channel may be a potential therapeutic target for podocyte injury and nephrotic syndrome.


  • Open Access

    Favorable therapeutic efficacy of low‐density lipoprotein apheresis for nephrotic syndrome with impaired renal function

    by Eri Muso, Soichi Sakai, Youske Ogura, Susumu Yukawa, Yoshiki Nishizawa, Noriaki Yorioka, Takao Saito, Masatoshi Mune, Satoshi Sugiyama, Yasuhiko Iino, et al.

    Many reports have shown the therapeutic efficacy of LDL apheresis (LDL‐A) in drug‐resistant nephrotic syndrome (NS) for improvement of heavy proteinuria and severely impaired renal function. To obtain comprehensive results in a large number of cases, a post hoc analysis of the Prospective Observational survey on the Long‐Term Effects of the LDL‐Apheresis on the Drug Resistant Nephrotic Syndrome (POLARIS) study was performed by stratifying enrolled cases according to the pretreatment estimated glomerular filtration rate (eGFR) levels indicating normal (N) (≥60 ml/min/1.73 m2), moderately impaired (M) (≥30 to 2), and severely impaired (S) (2) renal function. Significant improvements of proteinuria and renal function were found in Group N and, most interestingly, in Group M. A tendency for improvement in proteinuria was found in Group S. Most cases in all groups had not entered end‐stage renal disease at 2 years after LDL‐A treatment. These results suggest that LDL‐A has therapeutic efficacy even in cases in which renal function has declined to 30 ml/min/1.73 m2.


  • Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS)

    by Hitoshi Yokoyama, Ryohei Yamamoto, Enyu Imai, Shoichi Maruyama, Hitoshi Sugiyama, Kosaku Nitta, Tatsuo Tsukamoto, Shunya Uchida, Asami Takeda, Toshinobu Sato, et al.

    Background The aim of the present study was to clarify the prevalence of immunosuppressive drug use and outcomes in elderly and non-elderly patients with primary membranous nephropathy (MN) in nationwide real-world practice in Japan. Patients and methods Between 2009 and 2010, 374 patients with primary nephrotic syndrome were enrolled in the cohort study (The Japan Nephrotic Syndrome Cohort Study, JNSCS), including 126 adult patients with MN. Their clinical characteristics were compared with those of nephrotic patients with primary MN registered in a large nationwide registry (The Japan Renal Biopsy Registry, J-RBR). Outcomes and predictors in the elderly (≥ 65 years) and non-elderly groups were identified. Results Similar clinical characteristics were observed in JNSCS patients and J-RBR patients (n = 1808). At the early stage of 1 month, 84.1% of patients were treated with immunosuppressive therapies. No significant differences were observed in therapies between age groups. However, elderly patients achieved complete remission (CR) more frequently than non-elderly patients, particularly those treated with therapies that included corticosteroids. No significant differences were noted in serum creatinine (sCr) elevations at 50 or 100%, end-stage kidney disease, or all-cause mortality between age groups. Corticosteroids were identified as an independent predictor of CR (HR 2.749, 95%CI 1.593–4.745, p = 0.000) in the multivariate Cox’s model. sCr levels, hemoglobin levels, immunosuppressants, clinical remission, and relapse after CR were independent predictors of sCr × 1.5 or × 2.0. Conclusion Early immunosuppressive therapy including corticosteroids for primary MN showed better remission rates in elderly patients in a nationwide cohort study.


  • Open Access

    Phosphate binding by sucroferric oxyhydroxide ameliorates renal injury in the remnant kidney model

    by Yoshikazu Nemoto, Takanori Kumagai, Kenichi Ishizawa, Yutaka Miura, Takeshi Shiraishi, Chikayuki Morimoto, Kazuhiro Sakai, Hiroki Omizo, Osamu Yamazaki, Yoshifuru Tamura, et al.

    Recent clinical studies indicate that the disturbed phosphate metabolism in chronic kidney disease (CKD) may facilitate kidney injury; nonetheless, the causal role of phosphate in CKD progression remains to be elucidated. Here, we show that intestinal phosphate binding by sucroferric oxyhydroxide (SF) ameliorates renal injury in the rat remnant kidney model. Sprague-Dawley rats received 5/6 nephrectomy (RK) and had a normal chow or the same diet containing SF (RK + SF). RK rats showed increased plasma FGF23 and phosphate levels, which were suppressed by SF administration. Of note, albuminuria in RK rats was significantly ameliorated by SF at both 4 and 8 weeks. SF also attenuated glomerulosclerosis and tubulointerstitial injury. Moreover, several different approaches confirmed the protective effects on podocytes, explaining the attenuation of glomerulosclerosis and albuminuria observed in this study. As a possible mechanism, we found that SF attenuated renal inflammation and fibrosis in RK rats. Interestingly, von Kossa staining of the kidney revealed calcium phosphate deposition in neither RK nor RK + SF rats; however, plasma levels of calciprotein particles were significantly reduced by SF. These data indicate that latent positive phosphate balance accelerates CKD progression from early stages, even when overt ectopic calcification is absent.


  • Abstract 068: Kelch-Like 3 Dephosphorylation by Calcineurin as a Mechanism Regulating Na-cl Cotransporter

    by Qin Wang, Ken-Ichi Ishizawa, Osamu Yamazaki, Yoshifuru Tamura, Yoshihide Fujigaki, Shunya Uchida, Shigeru Shibata

    Tacrolimus, an inhibitor of the phosphatase calcineurin, is widely used as an immunosuppressive agent. However, its use is associated with hypertension and hyperkalemia. Although previous studies indicated that the activation of thiazide-sensitive, Na-Cl cotransporter (NCC) plays a key role in the pathogenesis, the identity of the direct target of calcineurin in kidney remained unclear. Kelch-like 3 (KLHL3) is a component of an E3 ubiquitin ligase that critically regulates NCC function. In pseudophyoaldoseronism type 2, the disease-causing mutations in KLHL3 impair binding and degradation of with-no-lysine 1 (WNK1) and WNK4, resulting in hypertension and hyperkalemia that are correctable by thiazide. Previously, we reported that phosphorylation of KLHL3 at serine 433 (KLHL3 S433-P ) by protein kinase C critically regulates KLHL3 function by abrogating the substrate-binding ability. However, phosphatases responsible for KLHL3 S433-P regulation were unknown. We here show that calcineurin acts as a phosphatase for KLHL3 S433-P . In in vitro phosphatase assay, we found that calcineurin suppressed KLHL3 S433-P levels (65% reduction from baseline). Consistently, the activation of calcineurin by ionomycin significantly reduced KLHL3 S433-P abundance in distal convoluted tubule cells and in HEK cells expressing KLHL3, an effect that was almost completely prevented by calcineurin knockdown. Moreover, we found that tacrolimus increased KLHL3 S433-P levels by 1.8 fold in mouse kidney, which was associated with the WNK accumulation and increased NCC activity. Finally, we found that tacrolimus attenuated KLHL3-mediated WNK4 ubiquitination and degradation, and this effect was abolished by non-phosphorylatable S433A substitution in KLHL3. These data identify Kelch-like 3 as a direct target of calcineurin, and provide evidence that KLHL3 is involved in the pathophysiology of tacrolimus-induced hypertension.

  • 高尿酸血症を有する血液透析患者におけるフェブキソスタットの薬物動態および有効性・忍容性の検討

    by Michito Nagura, Shinichiro Asakawa, Yosuke Kawamorita, Daigo Toyoki, Yoshifuru Tamura, Takanori Kumagai, Shigeru Shibata, Yoshihide Fujigaki, Shunya Uchida

  • Open Access

    Urinary Exosomal Aquaporin-2 Expression and the Efficacy of Tolvaptan in Advanced CKD Patients with Congestive Heart Failure: An Interim Report

    by Kenzo Kodaka, Emiko Kuribayashi Okuma, Shigeyuki Arai, Michito Nagura, Yoshifuru Tamura, Shigeru Shibata, Yoshihide Fujigaki, Shunya Uchida

    Background: The efficacy of tolvaptan, a selective antagonist for vasopressin V2 receptor, on water diuresis has been reported in congestive heart failure (CHF) patients with chronic kidney disease (CKD). However, the mechanism of tolvaptan resistance is not well understood. In this study the effect of tolvaptan on urinary expression of exosomal aquaporin-2 (AQP-2) was examined in relation to effectiveness of tolvaptan. Methods: We examined 13 CHF patients with advanced CKD (M:F=11:2, age 49 to 81, serum creatinine 1.7 to 10.4 mg/dL, eGFR 3.5 to 69 ml/min/1.73 m2, median 9.2) who were not under control with conventional treatment including furosemide therapy (40 to 80 mg orally). Tolvaptan of 7.5 mg/day was instituted and blood and urine parameters were measured as well as urinary exosomal AQP-2 and Na-K-2Cl cotransporter (NKCC2). Responders were defined as increase in urine volume greater than 500 ml/day after the treatment. Results: Eight patients were diagnosed as responders who increased urine volume together with decrease in body weight within several days (p<0.05 vs. before treatment). Baseline data did not show the significant difference between both groups. Serum levels of creatinine and Na did not change over 1 week in either responders or non-responders. All responders showed a significant reduction in urinary exosomal AQP-2 after the treatment whereas non-responders showed rather increase in its expression. In contrast, urinary exosomal NKCC2 expression was unaltered in any case. Conclusions: Tolvaptan exerts its diuretic action in more than half the CHF patients complicated with advanced CKD. The responsiveness corroborates well with urinary exosomal AQP2 expression. The predictor for resistance to tolvaptan needs further examination.

  • Open Access

    Uric Acid in the Follow-Up Determines 30% Decline in Estimated GFR Over 2 Years: a Propensity Score Analysis

    by Wen Xiu Chang, Ning Xu, Takanori Kumagai, Ryutaro Iijima, Kaito Waki, Masaki Yamanaka, Michito Nagura, Shigeyuki Arai, Yoshifuru Tamura, Shigeru Shibata, et al.

    Background/Aims: Higher level of serum uric acid (SUA) predicts early entry to dialysis in chronic kidney disease (CKD) patients. However, a short-term effect of SUA remains to be elucidated using a novel surrogate endpoint. Methods: Japanese CKD stage 3 to 4 patients were retrospectively examined (n= 701). The follow-up level of SUA was estimated as time-averaged uric acid (TA-UA). A propensity score for 6.0, 6.5 or 7.0 mg/dL of TA-UA was respectively calculated using baseline 23 covariates. The time-to-event analysis was performed for 30% decline in estimated GFR over 2 years. Results: Incidence rates over 2 years were 90 of 440 in men and 36 of 261 in women (p = 0.03). Despite the negative result of baseline SUA, stratified Cox regression on the quintiles of the estimated propensity score showed that higher TA-UA of the three thresholds were all significant (crude HR 2.10 to 2.44) even after adjusting for the confounders. Kaplan-Meier analysis after propensity score matching likewise showed worse survival in the patients with the higher TA-UA (HR 3.11 to 4.26). Conclusion: Higher SUA increases likelihood of reaching a surrogate endpoint over 2 years. Early intervention for SUA less than 6.0 mg/dL is recommended for slowing CKD progression.


  • Open Access

    Discontinuation of Hemodialysis in a Patient with Anti-GBM Disease by the Treatment with Corticosteroids and Plasmapheresis despite Several Predictors for Dialysis-Dependence

    by Yoshihide Fujigaki, Chikayuki Morimoto, Risa Iino, Kei Taniguchi, Yosuke Kawamorita, Shinichiro Asakawa, Daigo Toyoki, Shinako Miyano, Wataru Fujii, Tatsuru Ota, et al.

    A 26-year-old man highly suspected of having antiglomerular basement membrane (GBM) disease was treated with corticosteroid pulse therapy 9 days after initial infection-like symptoms with high procalcitonin value. The patient required hemodialysis the next day of the treatment due to oliguria. In addition to corticosteroid therapy, plasmapheresis was introduced and the patient could discontinue hemodialysis 43 days after the treatment. Kidney biopsy after initiation of hemodialysis confirmed anti-GBM disease with 86.3% crescent formation. Physician should keep in mind that active anti-GBM disease shows even high procalcitonin value in the absence of infection. To pursue recovery of renal function, the challenge of the immediate and persistent treatment with high-dose corticosteroids plus plasmapheresis for highly suspected anti-GBM disease is vitally important despite the presence of reported predictors for dialysis-dependence including oliguria and requiring hemodialysis at presentation.